Cure My Disease

Don't miss your cure!

 Log in / Sign up

New scan could reveal hidden organ damage without a biopsy

NCT ID NCT06974877

Recruiting now Diagnosis Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a radioactive tracer called 124I-AT-01 that binds to amyloid clumps in the body. Researchers want to see if PET/CT scans can detect amyloidosis in organs of people with CAPS who developed it from anakinra injections. Thirty adults will be scanned every 6 months for 2 years. The goal is to find a non-invasive way to track amyloid buildup over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
124I-AT-01 (a radioactive tracer for PET/CT scans)
What this could lead to
If successful, this could provide a non-invasive way to detect and monitor amyloid deposits in organs, reducing the need for biopsies.
What could go wrong
This is a very early phase 1 study with only 30 participants. The tracer may not reliably detect amyloid changes, and there is a small risk of inflammatory flare in people with CAPS.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYLOIDOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyloidosis CINCA syndrome cryopyrin-associated periodic syndrome Muckle-Wells syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AMYLOIDOSIS CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National Institutes of Health Clinical Center

    RECRUITING

    Bethesda, Maryland, 20892, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.